Anika Therapeutics to Refocus After Strategic Review

Anika Therapeutics reported 4Q23 orthopedic sales of $40.4 million, +9.7% compared to the fourth quarter of 2022. The company generated $156.8 million in orthopedic sales in 2023, growing 10.1% compared to the prior year.

Strong osteoarthritis pain management sales in the fourth quarter topped off a record year for that business, driven by...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us